Vector-Mediated In Vivo Antibody Expression.

Area of Science:

• Vaccinology
• Gene Therapy
• Immunology

Background:

• Current human immunodeficiency virus (HIV) vaccines struggle to elicit broadly neutralizing antibodies.
• Existing passive immunization methods require repeated protein administration.
• Need for alternative strategies to achieve sustained antibody-mediated protection against viral infections.

Purpose of the Study:

• To evaluate vector-mediated antibody gene transfer as a novel vaccine strategy.
• To assess the efficacy of delivering broadly neutralizing antibody genes using recombinant adeno-associated viral (rAAV) vectors.
• To demonstrate long-term protection against HIV and simian immunodeficiency virus (SIV) challenge.

Main Methods:

• Delivery of genes encoding broadly neutralizing antibodies into muscle tissue using rAAV vectors.
• Endogenous synthesis of antibodies in myofibers and passive distribution into the circulatory system.
• In vivo studies in mice and monkeys challenged with virulent HIV and SIV.

Main Results:

• Demonstrated long-lasting neutralizing antibody activity in serum following rAAV vector gene delivery.
• Achieved complete protection against intravenous challenge with virulent HIV and SIV in animal models.
• Confirmed efficient muscle transduction and long-term transgene expression by rAAV vectors.

Conclusions:

• Vector-mediated antibody gene transfer is a promising strategy for developing effective vaccines against HIV and other challenging pathogens.
• This approach overcomes limitations of traditional vaccines by allowing pre-determined antibody specificity and avoiding the need for an active immune response.
• The methodology holds potential for application to other difficult vaccine targets like hepatitis C virus, malaria, respiratory syncytial virus, and tuberculosis.